

ANTICANCER RESEARCH

International Journal of Cancer Research and Treatment

ISSN: 0250-7005

Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy and Sorafenib in Patients with Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization

MASAHIRO HATOOKA¹, TOMOKAZU KAWAOKA¹, HIROSHI AIKATA¹, KEI MORIO¹, TOMOKI KOBAYASHI¹, AKIRA HIRAMATSU¹, MICHIO IMAMURA¹, YOSHIKU KAWAKAMI¹, EISUKE MURAKAMI², KOJI WAKI², YOJI HONDA³, NAMI MORI³, SHINTARO TAKAKI³, KEIJI TSUJI³, HIROTAKA KOHNO⁴, HIROSHI KOHNO⁴, TAKASHI MORIYA⁵, MICHIIHIRO NONAKA⁶, HIDEYUKI HYOGO⁶, YASUYUKI AISAKA⁶ and KAZUAKI CHAYAMA¹

¹*Department of Medicine and Molecular Science, Division of Frontier Medical Science, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan;*

²*Hiroshima City Asa Hospital, Hiroshima, Japan;*

³*Hiroshima Red Cross Hospital, ⁴Kure Medical Center, Hiroshima, Japan;*

⁵*Chugoku Rousai Hospital, Hiroshima, Japan;*

⁶*Hiroshima General Hospital, Hiroshima, Japan*

Reprinted from

ANTICANCER RESEARCH 36: 3523-3530 (2016)

ANTICANCER RESEARCH

International Journal of Cancer Research and Treatment



ISSN (print): 0250-7005
ISSN (online): 1791-7530

Editorial Board

P. A. ABRAHAMSSON, Malmö, Sweden
B. B. AGGARWAL, Houston, TX, USA
T. AKIMOTO, Kashiwa, Chiba, Japan
P. Z. ANASTASIADIS, Jacksonville, FL, USA
A. ARGIRIS, San Antonio, TX, USA
J. P. ARMAND, Toulouse, France
V. I. AVRAMIS, Los Angeles, CA, USA
R. C. BAST, Houston, TX, USA
D.-T. BAU, Taichung, Taiwan, ROC
G. BAUER, Freiburg, Germany
E. E. BAULIEU, Le Kremlin-Bicetre, France
E. J. BENZ, Jr., Boston, MA, USA
J. BERGH, Stockholm, Sweden
F. T. BOSMAN, Lausanne, Switzerland
G. BROICH, Monza, Italy
Ø. S. BRULAND, Oslo, Norway
J. M. BUATTI, Iowa City, IA, USA
M. M. BURGER, Basel, Switzerland
M. CARBONE, Honolulu, HI, USA
C. CARLBERG, Kuopio, Finland
J. CARLSSON, Uppsala, Sweden
A. F. CHAMBERS, London, ON, Canada
P. CHANDRA, Frankfurt am Main, Germany
L. CHENG, Indianapolis, IN, USA
J.-G. CHUNG, Taichung, Taiwan, ROC
E. DE CLERCQ, Leuven, Belgium
W. DEN OTTER, Amsterdam, The Netherlands
E. P. DIAMANDIS, Toronto, ON, Canada
G. TH. DIAMANDOPOULOS, Boston, MA, USA
D. W. FELSHER, Stanford, CA, USA
J. A. FERNANDEZ-POL, Chesterfield, MO, USA
I. J. FIDLER, Houston, TX, USA
A. P. FIELDS, Jacksonville, FL, USA
B. FUCHS, Zurich, Switzerland
D. FUCHS, Innsbruck, Austria
G. GABBIANI, Geneva, Switzerland
R. GANAPATHI, Charlotte, NC, USA
A. F. GAZDAR, Dallas, TX, USA
J. H. GESCHWIND, Baltimore, MD, USA
A. GIORDANO, Philadelphia, PA, USA
G. GITSCH, Freiburg, Germany
R. H. GOLDFARB, Guilford, CT, USA
L. HELSON, Quakertown, PA, USA
R. M. HOFFMAN, San Diego, CA, USA
S. C. JHANWAR, New York, NY, USA
J. V. JOHANNESSEN, Oslo, Norway
B. KAINA, Mainz, Germany
P. -L. KELLOKUMPU-LEHTINEN, Tampere, Finland
D. G. KIEBACK, Schleswig, Germany
R. KLAPDOR, Hamburg, Germany
S. D. KOTTARIDIS, Athens, Greece
G. R. F. KRUEGER, Köln, Germany
Pat M. KUMAR, Manchester, UK

Shant KUMAR, Manchester, UK
O. D. LAERUM, Bergen, Norway
F. J. LEJEUNE, Lausanne, Switzerland
L. F. LIU, Piscataway, NJ, USA
D. M. LOPEZ, Miami, FL, USA
E. LUNDGREN, Umeå, Sweden
Y. MAEHARA, Fukuoka, Japan
J. MAHER, London, UK
J. MARESCAUX, Strasbourg, France
J. MARK, Skövde, Sweden
S. S. MARTIN, Baltimore, MD, USA
S. MITRA, Houston, TX, USA
S. MIYAMOTO, Fukuoka, Japan
M. MUELLER, Villingen-Schwenningen, Germany
F. M. MUGGIA, New York, NY, USA
M. NAMIKI, Kanazawa, Ishikawa, Japan
R. NARAYANAN, Boca Raton, FL, USA
K. NILSSON, Uppsala, Sweden
S. PATHAK, Houston, TX, USA
J.L. PERSSON, Malmö, Sweden
G. J. PILKINGTON, Portsmouth, UK
C. D. PLATSOUCAS, Norfolk, VA, USA
A. POLLIACK, Jerusalem, Israel
M. RIGAUD, Limoges, France
U. RINGBORG, Stockholm, Sweden
M. ROSELLI, Rome, Italy
A. SCHAUER, Göttingen, Germany
M. SCHNEIDER, Wuppertal, Germany
A. SETH, Toronto, ON, Canada
G. V. SHERBET, Newcastle-upon-Tyne, UK
G.-I. SOMA, Kagawa, Japan
G. S. STEIN, Burlington, VT, USA
T. STIGBRAND, Umeå, Sweden
T. M. THEOPHANIDES, Athens, Greece
P. M. UELAND, Bergen, Norway
H. VAN VLIERBERGHE, Ghent, Belgium
R. G. VILE, Rochester, MN, USA
M. WELLER, Zurich, Switzerland
B. WESTERMARK, Uppsala, Sweden
Y. YEN, Duarte, CA, USA
M.R.I. YOUNG, Charleston, SC, USA
B. ZUMOFF, New York, NY, USA

J. G. DELINASIOS, Athens, Greece
Managing Editor

G. J. DELINASIOS, Athens, Greece
Assistant Managing Editor and
Executive Publisher

E. ILIADIS, Athens, Greece
Production Editor

Editorial Office: International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O. Box 22, Attiki 19014, Greece. Tel / Fax: +30-22950-53389.

U.S. Branch: Anticancer Research USA, Inc., 111 Bay Avenue, Highlands, NJ 07732, USA.

E-mails: Editorial Office: journals@iia-anticancer.org

Managing Editor: editor@iia-anticancer.org

ANTICANCER RESEARCH supports: (a) the establishment and the activities of the INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH (IIAR; Kapandriti, Attiki, Greece); and (b) the organization of the International Conferences of Anticancer Research. The IIAR is a member of UICC. For more information about ANTICANCER RESEARCH, IIAR and the Conferences, please visit the IIAR website: www.iia-anticancer.org

Publication Data: ANTICANCER RESEARCH (AR) is published monthly from January 2009. Each annual volume comprises 12 issues. Annual Author and Subject Indices are included in the last issue of each volume. ANTICANCER RESEARCH Vol. 24 (2004) and onwards appears online with Stanford University HighWire Press from April 2009.

Copyright: On publication of a manuscript in AR, which is a copyrighted publication, the legal ownership of all published parts of the paper passes from the Author(s) to the Journal.

Annual Subscription Rates 2016 per volume: Institutional subscription US\$ 1,898.00 (online) or US\$ 2,277.00 (print & online). Personal subscription US\$ 897.00 (online) or US\$ 1,277.00 (print & online). Prices include rapid delivery and insurance. The complete previous volumes of Anticancer Research (Vol. 1-35, 1981-2015) are available at 50% discount on the above rates.

Subscription Orders: Orders can be placed at agencies, bookstores, or directly with the Publisher. (e-mail: subscriptions@iia-anticancer.org)

Advertising: All correspondence and rate requests should be addressed to the Editorial Office.

Book Reviews: Recently published books and journals should be sent to the Editorial Office. Reviews will be published within 2-4 months.

Articles in ANTICANCER RESEARCH are regularly indexed in all bibliographic services, including Current Contents (Life Sciences), Science Citation Index, Index Medicus, Biological Abstracts, PubMed, Chemical Abstracts, Excerpta Medica, University of Sheffield Biomedical Information Service, Current Clinical Cancer, AIDS Abstracts, Elsevier Bibliographic Database, EMBASE, Compendex, GEOBASE, EMBiology, Elsevier BIOBASE, FLUIDEX, World Textiles, Scopus, Progress in Palliative Care, Cambridge Scientific Abstracts, Cancergram (International Cancer Research Data Bank), MEDLINE, Reference Update - RIS Inc., PASCAL-CNRS, Inpharma-Reactions (Datastar, BRS), CABS, Immunology Abstracts, Telegen Abstracts, Genetics Abstracts, Nutrition Research Newsletter, Dairy Science Abstracts, Current Titles in Dentistry, Inpharma Weekly, BioBase, MedBase, CAB Abstracts/Global Health Databases, Investigational Drugs Database, VINITI Abstracts Journal, Leeds Medical Information, PubsHub, Sociedad Iberoamericana de Información Científica (SIIC) Data Bases.

Authorization to photocopy items for internal or personal use, or the internal or personal clients, is granted by ANTICANCER RESEARCH, provided that the base fee of \$2.00 per copy, plus 0.40 per page is paid directly to the Copyright Clearance Center, 27 Congress Street, Salem, MA 01970, USA. For those organizations that have been granted a photocopy license by CCC, a separate system of payment has been arranged. The fee code for users of the Transactional Reporting Service is 0250-7005/2016 \$2.00 +0.40.

The Editors and Publishers of ANTICANCER RESEARCH accept no responsibility for the opinions expressed by the contributors or for the content of advertisements appearing therein.

Copyright© 2016, International Institute of Anticancer Research (Dr. John G. Delinasios), All rights reserved.

D.T.P. BY IIAR

PRINTED BY ENTYP0, ATHENS, GREECE. PRINTED ON ACID-FREE PAPER

Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy and Sorafenib in Patients with Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization

MASAHIRO HATOOKA¹, TOMOKAZU KAWAOKA¹, HIROSHI AIKATA¹, KEI MORIO¹, TOMOKI KOBAYASHI¹, AKIRA HIRAMATSU¹, MICHIO IMAMURA¹, YOSHIKU KAWAKAMI¹, EISUKE MURAKAMI², KOJI WAKI², YOJI HONDA³, NAMI MORI³, SHINTARO TAKAKI³, KEIJI TSUJI³, HIROTAKA KOHNO⁴, HIROSHI KOHNO⁴, TAKASHI MORIYA⁵, MICHIIHIRO NONAKA⁶, HIDEYUKI HYOGO⁶, YASUYUKI AISAKA⁶ and KAZUAKI CHAYAMA¹

¹Department of Medicine and Molecular Science, Division of Frontier Medical Science, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan;

²Hiroshima City Asa Hospital, Hiroshima, Japan;

³Hiroshima Red Cross Hospital, ⁴Kure Medical Center, Hiroshima, Japan;

⁵Chugoku Rousai Hospital, Hiroshima, Japan;

⁶Hiroshima General Hospital, Hiroshima, Japan

Abstract. Aim: To compare the outcome of 5-fluorouracil (FU)-based hepatic arterial infusion chemotherapy (HAIC) with sorafenib monotherapy in patients with hepatocellular carcinoma (HCC) refractory to transcatheter arterial chemoembolization (TACE). Patients and Methods: In this retrospective cohort study, 123 patients with HCC refractory to TACE, with Child-Pugh A and free of extrahepatic metastasis, were divided into two groups: 65 received HAIC and 58 received sorafenib. Since the size of main tumor and portal vein invasion were significantly different between the HAIC and sorafenib groups, we selected 48 patients from the 65 patients of the HAIC group and 48 from the 58 patients of the sorafenib group. The model used one-to-one matching between the two groups using the case-control method matching method. The clinical characteristics of patients of the case-control HAIC (n=48) and sorafenib groups (n=48) were similar. Overall survival, time to progression and time to treatment failure (TTTF) were compared between the two groups. Results: The

median survival time and TTTF were significantly longer in the sorafenib group than in the HAIC group (15 and 12.2 months versus 8 and 4.4 months, respectively; $p=0.021$ and $p=0.002$, respectively). Multivariate analysis identified male gender ($p=0.008$), relative tumor size $<50\%$ ($p=0.012$), α -fetoprotein <400 ng/ml ($p=0.005$), and treatment with sorafenib ($p=0.001$) as significant and independent determinants of better overall survival. Conclusion: In patients with HCC refractory to TACE, overall survival was favorable in those treated with sorafenib rather than HAIC.

Several studies have reported on clinical benefits of sorafenib in patients with advanced hepatocellular carcinoma (HCC), including a placebo-controlled randomized phase III study (1) and a phase III study performed in the Asia-Pacific region (2). Sorafenib is currently the only standard therapy in many countries for patients with advanced HCC and extrahepatic metastasis, unresectable HCC, refractory to transcatheter arterial chemoembolization (TACE) and with macroscopic vascular invasion (MVI). Sorafenib is reported to prolong overall survival by 2.3-2.8 months and improve the response rate (RR) by 2.0-3.3%, compared to placebo (1). Sorafenib also has favorable results in patients with disease refractory to TACE compared to hepatic arterial infusion chemotherapy (HAIC) using cisplatin, with a significantly higher disease control rate, longer time to progression and increased overall survival (3).

HAIC is widely used in Asia, especially in Japan. The regimens used in HAIC include cisplatin only, interferon

Correspondence to: Hiroshi Aikata, MD, Department of Medicine and Molecular Science, Division of Frontier Medical Science, Programs for Biomedical Research, Graduate School of Biomedical Sciences, Hiroshima University, 1-2-3, Kasumi, Minami-ku, Hiroshima 734-8551, Japan. Tel: +81 822575192, Fax: +81 822575194, e-mail: aikata@hiroshima-u.ac.jp

Key Words: HCC, sorafenib, hepatic arterial infusion chemotherapy, transcatheter arterial chemoembolization.

plus 5-fluorouracil (5-FU), or cisplatin plus 5-FU. Several studies have shown the survival benefits of HAIC for advanced HCC without extrahepatic metastasis, with response rates ranging from 20.8 to 52% (4-9). The reported median survival time (MST) in complete and partial responders is about 40 and 17 months, respectively (4-9). In the majority of retrospective studies, survival was significantly better in responders to HAIC than non-responders (5, 6). In HAIC, the response rate to sorafenib is usually high and responders have good overall survival (1, 6). However, the response rate and overall survival are poor in patients with extrahepatic metastasis (10). Furthermore, the survival of patients with Child-Pugh class B cirrhosis is significantly inferior to that of patients with Child-Pugh class A treated with HAIC (9), and the RR and overall survival are poorer in patients with disease refractory to TACE (11).

To our knowledge, there are no studies to have compared the benefits of 5-FU-based-HAIC treatment with sorafenib monotherapy in patients with HCC refractory to TACE. In this retrospective cohort study, we compared the response to HAIC therapy to that of sorafenib monotherapy in patients with TACE-refractory Child-Pugh A HCC, free from extrahepatic metastasis.

Patients and Methods

Patients. In this retrospective cohort study, among 325 patients treated by HAIC and 391 patients treated with sorafenib at our and affiliated hospitals, we enrolled only 123 patients with HCC, Child-Pugh A cirrhosis, free from extrahepatic metastasis and refractory to TACE. We excluded patients who were treated with both HAIC and sorafenib during the follow-up period. The study included 65 patients who received HAIC only and 58 who received sorafenib monotherapy.

Refractoriness to TACE was assessed radiologically on baseline computed tomography (CT)/magnetic resonance imaging (MRI) (taken within 3 months of TACE) according to the 2010 JSH Consensus Guidelines (12), and also by changes in tumor markers within 2 months of TACE. For the latter, persistent elevation of α -fetoprotein (AFP) within 2 months after TACE exceeding 20% relative to the baseline (before TACE) was considered non-response.

HAIC. HAIC consisted of repeated arterial infusions of anticancer agents via the injection port. Two drug regimens were used: intra-arterial low-dose cisplatin combined with 5-FU therapy (FP) and intra-arterial 5-FU with subcutaneous interferon (IFN) combination therapy (5-FU+IFN). One course of chemotherapy continued for 2 weeks. 5-FU at 300 mg/kg body weight/day was administered over 24 hours using a mechanical infusion pump from days 1 to 5 of the first and second weeks in both regimens. Cisplatin was injected intra-arterially at 6 mg/kg body weight/day on days 1-5 and 8-12. The IFN used in the 5-FU+IFN regimen was recombinant IFN α -2b or natural IFN- α , administered intramuscularly on days 1, 3, and 5 of each week (total dose, 36 and 60 MU, respectively). A 2- to 4-week rest period of no treatment was allowed after each treatment course (9). A total of 28 patients received FP, while 37 patients received 5FU+IFN.

Sorafenib monotherapy. Treatment with sorafenib was used between June 2009 and December 2015, at a dose of 400 mg twice daily. Treatment interruptions and dose reductions (to 400 mg once daily) were permitted for adverse drug reactions. Patients continued sorafenib monotherapy as long as possible, even when disease progression was noted, until death, or meeting one of the following criteria for cessation of therapy: adverse events that required termination of treatment, deterioration of Eastern Cooperative Oncology Group performance status (ECOG PS) to 4, worsening liver function, or withdrawal of consent. The criterion for liver function for treatment discontinuation was a total bilirubin level >3 mg/dl at 4 weeks after cessation of treatment.

Assessment of response to therapy and safety. The response to treatment was evaluated by the Response Evaluation Criteria in Solid Tumors (RECIST) (13) after completion of each course and at 8 weeks. As part of the assessment, each patient underwent dynamic CT or MRI every 3-4 months. Overall survival was assessed from the date of initiation of therapy until the date of death from any cause.

Safety was assessed by adverse drug reactions, clinical laboratory tests, physical examination, and measurement of vital signs. Adverse drug reactions were defined according to the Common Terminology Criteria for Adverse Events version 4.0 (14).

Statistical analysis. Continuous variables were expressed as the mean, while categorical variables were expressed as absolute and relative frequencies. Univariate analysis was used to investigate the relationship between overall survival of patients refractory to TACE after initiation of therapy and various clinicopathological variables. Overall survival was studied by Kaplan–Meier survival curves with log-rank survival comparisons and 95% confidence interval (CI). A Cox proportional hazards model was used to identify the prognostic factors for overall survival.

Since the size of the main tumor, portal vein invasion (Vp) and des- γ -carboxy prothrombin (DCP) were significantly different between the HAIC and sorafenib groups (see Results), we selected 48 patients from the 65 patients of the HAIC group and 48 from the 58 patients of the sorafenib group. The model used one-to-one matching between the two groups by using the case–control matching method (15).

A *p*-value less than 0.05 denoted the presence of a statistically significant difference. All statistical analyses were carried out with the Predictive Analytics Software v21.0 (IBM Corp., Armonk, NY, USA).

Results

Patients' clinical characteristics. Table I lists the differences between patients of the HAIC-treated and sorafenib-treated groups. Since the size of main tumor and Vp were significantly different between the two groups, we selected 48 patients from the 65 patients of the HAIC-treated group and 48 from the 58 patients of the sorafenib-treated group (Figure 1). The model used one-to-one match between the two groups by using the case–control method matching method. Table II shows that the clinical characteristics of patients of the case–control HAIC (n=48) and sorafenib groups (n=48) were similar. These patients

Table I. Characteristics of patients with hepatocellular carcinoma refractory to transcatheter arterial chemoembolization.

Characteristic	HAIC (n=65)	Sorafenib (n=58)	p-Value
Age (range), years	67 (46-84)	70 (50-88)	0.08
Gender (male/female)	59/6	43/15	0.05
PS (0/1)	63/2	54/4	1.0
HBV/HCV/NBNC	15/43/7	13/40/5	0.8
Platelet count (range), $\times 10^4/\mu\text{l}$	12.2 (4.6-88.8)	15.3 (5.3-20.7)	0.4
Size of main tumor (range), mm	40 (15-140)	32 (5-190)	0.017
Relative tumor size (<50%/≥50%)	52/13	40/18	0.4
Vp (0-2/3-4)	42/23	52/6	0.001
No. of tumors (solitary/multiple)	17/48	24/34	0.1
TMN stage II/III/IVa	4/27/34	10/42/6	0.001
BCLC (B/C)	42/23	52/6	0.001
AFP (range), ng/ml	415.3 (5-191500)	449 (5-2446)	0.2
DCP (range), mAU/ml	370 (7-16163)	414 (14-58970)	0.06
No. of prior TACE sessions (range)	4 (2-9)	3 (2-8)	0.1

PS: Performance status, HBV: hepatitis B viral infection, HCV: hepatitis C viral infection, NBNC: non-B-non-C viral hepatitis, Vp: portal vein invasion, TMN: TMN Classification of Malignant Tumors, BCLC: Barcelona Clinic Liver Cancer Staging classification, AFP: α -fetoprotein, DCP: *des*- γ -carboxy prothrombin. Data are median values.

Table II. Characteristics of patients with hepatocellular carcinoma refractory to transcatheter arterial chemoembolization for the case-control method.

Characteristic	HAIC (n=48)	Sorafenib (n=48)	p-Value
Age (range), years	68 (46-83)	68 (50-88)	0.5
Gender male/female, n	42/6	36/12	0.19
PS 0/1, n	46/2	45/3	0.55
HBV/HCV/NBNC, n	11/32/5	12/33/3	1.0
Platelet count (range), $\times 10^4/\mu\text{l}$	12.2 (4.6-88.8)	15.3 (5.3-20.7)	0.4
Size of main tumor (range), mm	38 (15-140)	33 (10-80)	0.23
Relative tumor size, (<50%/≥50%) ,n	40/8	37/11	1.0
Vp, 0-2/3-4, n	42/6	42/6	1.0
No. of tumors, solitary/multiple	9/39	9/39	1.0
TMN stage II/III/IVa, n	2/40/6	2/40/6	1.0
BCLC, B/C, n	42/6	42/6	1.0
AFP (range), ng/ml	415.3 (5-191500)	305 (5-12230)	0.5
DCP (range), mAU/ml	338 (7-13044)	412 (14-9300)	0.5
No. of prior TACE sessions (range)	4 (2-9)	3 (2-8)	0.1

HAIC: Hepatic arterial infusion chemotherapy, PS: performance status, HBV: hepatitis B viral infection, HCV: hepatitis C viral infection, NBNC: non-B-non-C viral hepatitis, Vp: portal vein invasion, TMN: TMN Classification of Malignant Tumors, BCLC: Barcelona Clinic Liver Cancer Staging classification, AFP: α -fetoprotein, DCP: *des*- γ -carboxy prothrombin. Data are median values.

met the study eligibility criteria and were matched for age, gender, etiology, platelet count, tumor size, Vp, TNM stage, Barcelona Clinic Liver Cancer Staging classification (BCLC), AFP, and DCP.

Response to therapy. The proportions of patients with complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD) were 0%, 12%, 54% and 27% for the HAIC group, and 2%, 4%, 60% and 27% for

the sorafenib group. The response rate was similar for the HAIC and sorafenib groups (12% and 6%, $p=0.4$).

The median survival time was better in the sorafenib group (months) than the HAIC group (15 *versus* 8 months, $p=0.021$; Figure 2a). The time to progression was also similar (2.8 months *versus* 4.0 months, respectively, $p=0.5$; Figure 2b). The time to treatment failure was longer in the sorafenib group (12.2 *versus* 4.4 months, respectively, $p=0.001$; Figure 2c). For the MST of patients treated with




Figure 1. Flow-chart of patient recruitment.

HAIC, there was no significant difference between those treated with FP and those treated with 5-FU+IFN.

The MST was longer in patients of the sorafenib group with CR (n=1). The MST of the patients with PR in the sorafenib (n=2) and HAIC (n=6) groups was 33 and 19 months, respectively ($p=0.1$); while for those with SD, the MST was 18 (n=29) and 12 (n=26) months, respectively ($p=0.3$). Furthermore, the MST of the patients with PD was 9 (n=13) and 3 (n=13) months, respectively ($p=0.001$).

Determinants of overall survival. Overall survival correlated significantly with gender ($p=0.012$), relative tumor size ($p=0.049$), Vp ($p=0.0001$), AFP ($p=0.005$) and treatment type ($p=0.001$). Multivariate analysis identified male gender ($p=0.008$) relative tumor size <50% ($p=0.012$), AFP <400 ng/ml ($p=0.005$), and treatment with sorafenib ($p=0.001$) as significant and independent determinants of better overall survival (Table III).

Overall survival according to MVI. In the HAIC group, the MST was not different between Vp0-2 (9 months) and Vp3-4 (7 month; $p=0.5$, Figure 3a), nor did it differ in the sorafenib group (12 versus 19 months, respectively, $p=0.3$; Figure 3b).

Adverse events. In the HAIC group, CTCAE grade 3/4 liver failure occurred in two patients (4.0%), hypersensitivity reaction to cisplatin in one patient (2.0%) and infection of the injection port in one (2.2%). In the sorafenib group, CTCAE grade 3/4 worsening of PS occurred in one patient (2.2%) and diarrhea and general fatigue in one patient (2.2%).

Discussion

Sorafenib is standard treatment for HCC refractory to TACE (16). The appearance of extrahepatic metastasis, MVI and enlargement of hepatic tumor are examples of lack of response to TACE. In this study, we selected patients with Child-Pugh A who were free of extrahepatic metastases and refractory to TACE. We also excluded patients who were treated with both HAIC and sorafenib during the follow-up period. In such patients, a switch to sorafenib is recommended rather than continuation of TACE (17). Another study reported that sorafenib is better than HAIC using cisplatin for HCC refractory to TACE (3). To our knowledge, however, there are no studies that compared sorafenib with HAIC using 5-FU for patients who failed to respond to TACE. For the above reasons, the present study was designed to compare the response to 5-FU-based HAIC and sorafenib in HCC refractory to TACE in patients with Child-Pugh A cirrhosis, free from extrahepatic metastasis.

Strict comparisons with previous studies is sometimes difficult since such studies included patients whose disease was not refractory to TACE and the patient selection process allowed potential biases. For example, in the study of Ikeda *et al.*, 33% and 45% of patients treated with sorafenib and HAIC, respectively, had Child-Pugh B cirrhosis (3). This is important, since Child-Pugh B cirrhosis is a well-known poor prognostic factor in patients treated with sorafenib. Another limitation of the above study was inclusion of eight out of 66 (12%) patients who were switched from HAIC to sorafenib.






Figure 2. Overall survival (a), time to progression (b), and time to treatment failure (c) for hepatic arterial infusion chemotherapy (HAIC) and sorafenib in patients with hepatocellular carcinoma.





Figure 3. Overall survival after hepatic arterial infusion chemotherapy (HAIC) (a) and sorafenib (b) therapy of hepatocellular carcinoma according to portal vein invasion (Vp). Vp 0, No tumor thrombus; Vp, one tumor thrombus in the second branch of the portal vein; Vp 3, tumor thrombus in the first branch of the portal vein; Vp 4, tumor thrombus in the trunk of the portal vein.

Our results showed that sorafenib provided a better MST (15 months) than HAIC (8 months). The first reason for this is that the time to treatment failure of sorafenib is longer than HAIC: patients who received sorafenib were treated for a longer period than those treated with HAIC. The second reason is the need to withdraw treatment due to stenosis of the hepatic artery by catheter therapy, reduced sensitivity to the drug, deterioration of liver function, or the appearance of collateral arteries.

Table III. Results of univariate and multivariate analyses for prognostic factors in patients with hepatocellular carcinoma refractory to transcatheter arterial chemoembolization.

	Univariate				Multivariate			
	N	Median (months)	HR	95% CI	p-Value	HR	95% CI	p-Value
Age (years)								
<67	48	13	0.6	0.4-1.03	0.069			
≥67	48	10	1.0					
Gender								
Male	78	12.2	0.4	0.20-0.8	0.012	0.23	0.2-0.8	0.008
Female	18	8	1.0					
Etiology								
HCV	65	11.3	1.0	0.3-1.3	0.2			
Other	23	8.9	1.0					
Platelet count (×10 ⁴ /μl)								
<15	48	11.3	1.0	0.3-1.3	0.2			
≥15	48	8.9	1.0					
Size of main tumor (mm)								
≥38	48	8.9	1.4	1.03-2.5	0.035			
<38	48	16	1.0					
Relative tumor size								
≥50%	68	6	1.6	0.9-3.0	0.049	2.2	1.1-4.3	0.012
<50%	18	13	1.0					
Vp								
3-4	12	3	3.7	1.8-7.7	0.0001	4.4	1.9-9.9	0.0001
0-2	84	12	1.0					
No. of tumors								
Multiple	78	10	0.3	0.04-2.5	0.2			
Solitary	18	19	1.0					
AFP (ng/ml)								
≥400	48	7	1.7	1.1-2.8	0.01	2.1	1.2-3.6	0.005
<400	48	16	1.0					
DCP (mAU/ml)								
≥400	48	10.2	0.2	0.3-1.1	1.3			
<400	48	11.3	1.0					
Treatment								
Sorafenib	48	15	0.4	0.2-0.8	0.007	0.3	0.2-0.6	0.001
HAIC	48	8	1.0					

HR: Hazard ratio, CI: confidence interval, PS: performance status, HBV: hepatitis B viral infection, HCV: hepatitis C viral infection, NBNC: non-B-non-C viral hepatitis, Vp: portal vein invasion, TMN: TMN Classification of Malignant Tumors, BCLC: Barcelona Clinic Liver Cancer Staging classification, AFP: α -fetoprotein, DCP: *des*- γ -carboxy prothrombin.

In both groups, the MST was not significantly different between Vp0-2 and Vp3-4. Generally, among patients with MVI, it has been reported that HAIC provides more favorable survival than sorafenib (18). However, in the present study, in which the subject was TACE-refractory patients, the superiority of HAIC to sorafenib was not demonstrated among patients with MVI. This might be due to stenosis of the hepatic artery by catheter therapy, or reduced sensitivity to the drug.

Our study has certain limitations. Firstly, the study included only a small number of patients and was retrospective in nature.

However, we selected patients with Child-Pugh A cirrhosis who were free of extrahepatic metastasis and refractory to TACE. We also excluded patients who were treated with both HAIC and sorafenib during the follow-up period, thus allowing us to study selected groups of patients. We believe that the present study provides important information on the management of patients with HCC refractory to TACE.

In conclusion, sorafenib led to favorable overall survival among HCC patients refractory to TACE compared to those treated with HAIC. Further large-scale prospective studies are needed to compare the effects of HAIC with sorafenib.

References

- 1 Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Haussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D and Bruix J: Sorafenib in advanced hepatocellular carcinoma. *N Engl J Med* 359(4): 378-390, 2008.
- 2 Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D and Guan Z: Efficacy and safety of sorafenib in patients in the asia-pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial. *Lancet Oncol* 10(1): 25-34, 2009.
- 3 Ikeda M, Mitsunaga S, Shimizu S, Ohno I, Takahashi H, Okuyama H, Kuwahara A, Kondo S, Morizane C, Ueno H, Satake M, Arai Y and Okusaka T: Efficacy of sorafenib in patients with hepatocellular carcinoma refractory to transcatheter arterial chemoembolization. *J Gastroenterol* 49(5): 932-940, 2014.
- 4 Ando E, Tanaka M, Yamashita F, Kuromatsu R, Yutani S, Fukumori K, Sumie S, Yano Y, Okuda K and Sata M: Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: Analysis of 48 cases. *Cancer* 95(3): 588-595, 2002.
- 5 Obi S, Yoshida H, Toune R, Unuma T, Kanda M, Sato S, Tateishi R, Teratani T, Shiina S and Omata M: Combination therapy of intraarterial 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma with portal venous invasion. *Cancer* 106(9): 1990-1997, 2006.
- 6 Uka K, Aikata H, Takaki S, Miki D, Kawaoka T, Jeong SC, Takahashi S, Toyota N, Ito K and Chayama K: Pretreatment predictor of response, time to progression, and survival to intraarterial 5-fluorouracil/interferon combination therapy in patients with advanced hepatocellular carcinoma. *J Gastroenterol* 42(10): 845-853, 2007.
- 7 Uka K, Aikata H, Takaki S, Miki D, Jeong SC, Hiramatsu A, Kodama H, Shirakawa H, Kawakami Y, Takahashi S, Toyota N, Ito K and Chayama K: Similar effects of recombinant interferon-alpha-2b and natural interferon-alpha when combined with intraarterial 5-fluorouracil for the treatment of advanced hepatocellular carcinoma. *Liver Int* 27(9): 1209-1216, 2007.
- 8 Katamura Y, Aikata H, Takaki S, Azakami T, Kawaoka T, Waki K, Hiramatsu A, Kawakami Y, Takahashi S, Kenjo M, Toyota N, Ito K and Chayama K: Intra-arterial 5-fluorouracil/interferon combination therapy for advanced hepatocellular carcinoma with or without three-dimensional conformal radiotherapy for portal vein tumor thrombosis. *J Gastroenterol* 44(5): 492-502, 2009.
- 9 Miyaki D, Aikata H, Honda Y, Naeshiro N, Nakahara T, Tanaka M, Nagaoki Y, Kawaoka T, Takaki S, Waki K, Hiramatsu A, Takahashi S, Ishikawa M, Kakizawa H, Awai K and Chayama K: Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma according to Child-Pugh classification. *J Gastroenterol Hepatol* 27(12): 1850-1857, 2012.
- 10 Katamura Y, Aikata H, Kimura Y, Kawaoka T, Takaki S, Waki K, Hiramatsu A, Kawakami Y, Takahashi S, Ishikawa M, Hieda M, Kakizawa H and Chayama K: Intra-arterial 5-fluorouracil/interferon combination therapy for hepatocellular carcinoma with portal vein tumor thrombosis and extrahepatic metastases. *J Gastroenterol Hepatol* 25(6): 1117-1122, 2010.
- 11 Kirikoshi H, Yoneda M, Mawatari H, Fujita K, Imajo K, Kato S, Suzuki K, Kobayashi N, Kubota K, Maeda S, Nakajima A and Saito S: Is hepatic arterial infusion chemotherapy effective treatment for advanced hepatocellular carcinoma resistant to transarterial chemoembolization? *World J Gastroenterol* 18(16): 1933-1939, 2012.
- 12 Kudo M, Izumi N, Kokudo N, Matsui O, Sakamoto M, Nakashima O, Kojiro M, Makuuchi M and Hepatology HCCEPoJSo: Management of hepatocellular carcinoma in Japan: Consensus-based clinical practice guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. *Dig Dis* 29(3): 339-364, 2011.
- 13 Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D and Verweij J: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). *Eur J Cancer* 45(2): 228-247, 2009.
- 14 Arnold B, Mitchell SA, Lent L, Mendoza TR, Rogak LJ, Barragan NM, Willis G, Medina M, Lechner S, Penedo FJ, Harness JK, Basch EM, Translation P-CS and Linguistic Validation Study G: Linguistic validation of the spanish version of the national cancer institute's patient-reported outcomes version of the common terminology criteria for adverse events (Pro-CTCAE). *Support Care Cancer* 24(7): 2843-2851, 2016.
- 15 Clarke M and Clayton D: The design and interpretation of case-control studies of perinatal mortality. *Am J Epidemiol* 113(6): 636-645, 1981.
- 16 Kokudo N, Hasegawa K, Akahane M, Igaki H, Izumi N, Ichida T, Uemoto S, Kaneko S, Kawasaki S, Ku Y, Kudo M, Kubo S, Takayama T, Tateishi R, Fukuda T, Matsui O, Matsuyama Y, Murakami T, Arii S, Okazaki M and Makuuchi M: Evidence-based clinical practice guidelines for hepatocellular carcinoma: The Japan Society of Hepatology 2013 update (3rd JSH-HCC guidelines). *Hepatol Res* 45(2), 2015.
- 17 Ogasawara S, Chiba T, Ooka Y, Kanogawa N, Motoyama T, Suzuki E, Tawada A, Kanai F, Yoshikawa M and Yokosuka O: Efficacy of sorafenib in intermediate-stage hepatocellular carcinoma patients refractory to transarterial chemoembolization. *Oncology* 87(6): 330-341, 2014.
- 18 Song DS, Song MJ, Bae SH, Chung WJ, Jang JY, Kim YS, Lee SH, Park JY, Yim HJ, Cho SB, Park SY and Yang JM: A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis. *J Gastroenterol* 50(4): 445-454, 2015.

Received April 28, 2016

Revised June 9, 2016

Accepted June 10, 2016

Instructions for Authors 2016

General Policy. ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts and Proceedings of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer, and (d) Announcements of awards and prizes.

The principal aim of AR is to provide prompt publication (print and online) for original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works in the field of cancer research that are not under consideration for publication by another journal, and that they will not be published again in the same form. All authors should sign a submission letter confirming the approval of their article contents. All material submitted to AR will be subject to review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

NIH Open Access Policy. The journal acknowledges that authors of NIH-funded research retain the right to provide a copy of the published manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

Copyright. Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has been transferred from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without the written consent of the Managing Editor or Publisher.

Format. Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the "Shorter Oxford English Dictionary".

Manuscripts. Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double - spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding 4 printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections:

(a) *First page* including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication "review", "clinical", "epidemiological", or "experimental" study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) *Abstract* not exceeding 150 words, organized according to the following headings: Background/Aim - Materials and Methods/Patients and Methods - Results - Conclusion; (c) *Introduction*; (d) *Materials and Methods/Patients and Methods*; (e) *Results*; (f) *Discussion*; (g) *Acknowledgements*; (h) *References*. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

Figures. All figures should appear at the end of the submitted document file. Once a manuscript is accepted all figures and graphs should be submitted separately in either jpg, tiff or pdf format and at a minimum resolution of 300 dpi. Graphs must be submitted as pictures made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated. Pages that include color figures are subject to color charges.

Tables. All tables should appear at the end of the submitted document file. Once a manuscript is accepted, each table should be submitted separately, typed double-spaced. Tables should be numbered with Roman numerals and should include a short title.

References. Authors must assume responsibility for the accuracy of the references used. Citations for the reference sections of submitted works should follow the standard form of "Index Medicus" and must be numbered consecutively. In the text, references should be cited by number. Examples: 1 Sumner AT: The nature of chromosome bands and their significance for cancer research. *Anticancer Res* 1: 205-216, 1981. 2 McGuire WL and Chamnes GC: Studies on the oestrogen receptor in breast cancer. In: *Receptors for Reproductive Hormones* (O' Malley BW, Chamnes GC (eds.). New York, Plenum Publ Corp., pp 113-136, 1973.

Nomenclature and Abbreviations. Nomenclature should follow that given in "Chemical Abstracts", "Index Medicus", "Merck Index", "IUPAC –IUB", "Bergey's Manual of Determinative Bacteriology", The CBE Manual for Authors, Editors and Publishers (6th edition, 1994), and MIAME Standard for Microarray Data. Human gene symbols may be obtained from the HUGO Gene Nomenclature Committee (HGNC) (<http://www.gene.ucl.ac.uk/>). Approved mouse nomenclature may be obtained from <http://www.informatics.jax.org/>. Standard abbreviations are preferable. If a new abbreviation is used, it must be defined on first usage.

Clinical Trials. Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by "ISRCTN"). Please note that there is no space between the prefix "ISRCTN" and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by 'NCT'). Please note that there is no space between the prefix 'NCT' and the number. Example: NCT00001789.

Ethical Policies and Standards. ANTICANCER RESEARCH agrees with and follows the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals" established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 (www.icmje.org). Microarray data analysis should comply with the "Minimum Information About Microarray Experiments (MIAME) standard". Specific guidelines are provided at the "Microarray Gene Expression Data Society" (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human foetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

Submission of Manuscripts. Please follow the Instructions for Authors regarding the format of your manuscript and references.

Manuscripts must be submitted only through our online submission system at: <http://www.iiar-submissions.com/login.html>

In case a submission is incomplete, the corresponding Author will be notified accordingly.

Questions regarding difficulties in using the online submission system should be addressed to: email: journals@iiar-anticancer.org

Galley Proofs. Unless otherwise indicated, galley proofs will be sent to the corresponding Author of the submission. Corrections of galley proofs should be limited to typographical errors. Reprints, PDF files, and/or Open Access may be ordered after the acceptance of the paper. Authors of online open access articles are entitled to a complimentary online annual subscription to Anticancer Research for the current year. Requests should be addressed to the Editorial Office. Galley proofs should be returned corrected to the Editorial Office by email within two days.

Specific information and additional instructions for Authors

1. Anticancer Research (AR) closely follows the new developments in all fields of experimental and clinical cancer research by (a) inviting reviews on topics of immediate importance and substantial progress in the last three years, and (b) providing the highest priority for rapid publication to manuscripts presenting original results judged to be of exceptional value. Theoretical papers will only be considered and accepted if they bear a significant impact or formulate existing knowledge for the benefit of research progress.
2. Anticancer Research will consider the publication of conference proceedings and/or abstracts provided that the material submitted fulfils the quality requirements and instructions of the journal, following the regular review process by two suitable referees. (For further information please click [here](#))
3. An acknowledgement of receipt, including the article number, title and date of receipt is sent to the corresponding author of each manuscript upon receipt. If this receipt is not received within 20 days from submission, the author should call or write to the Editorial Office to ensure that the manuscript (or the receipt) was not lost in the mail or during electronic submission.
4. Each manuscript submitted to AR is sent for review in confidence to two suitable referees with the request to return the manuscript with their comments to the Editorial Office within 12 days from receipt. If reviewers need a longer time or wish to send the manuscript to another expert, the manuscript may be returned to the Editorial Office with a delay. All manuscripts submitted to AR, are treated in confidence, without access to any person other than the Managing Editor, the journal's secretary, the reviewers and the printers.

5. All accepted manuscripts are peer-reviewed and carefully corrected in style and language, if necessary, to make presentation clear. (There is no fee for this service). Every effort is made (a) to maintain the personal style of the author's writing and (b) to avoid change of meaning. Authors will be requested to examine carefully manuscripts which have undergone language correction at the pre-proof or proof stage.
 6. Authors should pay attention to the following points when writing an article for AR:
 - The Instructions to Authors must be followed in every detail.
 - The presentation of the experimental methods should be clear and complete in every detail facilitating reproducibility by other scientists.
 - The presentation of results should be simple and straightforward in style. Results and discussion should not be combined into one section, unless the paper is short.
 - Results given in figures should not be repeated in tables.
 - Figures (graphs or photographs) should be prepared at a width of 8 or 17 cm with legible numbers and lettering.
 - Photographs should be clear with high contrast, presenting the actual observation described in the legend and in the text. Each legend should provide a complete description, being self-explanatory, including technique of preparation, information about the specimen and magnification.
 - Statistical analysis should be elaborated wherever it is necessary. Simplification of presentation by giving only numerical or % values should be avoided.
 - Fidelity of the techniques and reproducibility of the results, should be points of particular importance in the discussion section. Authors are advised to check the correctness of their methods and results carefully before writing an article. Probable or dubious explanations should be avoided.
 - Authors should not cite results submitted for publication in the reference section. Such results may be described briefly in the text with a note in parenthesis (submitted for publication by... authors, year).
 - The References section should provide as complete a coverage of the literature as possible including all the relevant works published up to the time of submission.
 - By following these instructions, Authors will facilitate a more rapid review and processing of their manuscripts and will provide the readers with concise and useful papers.
 7. Following review and acceptance, a manuscript is examined in language and style, and galley proofs are rapidly prepared. Second proofs are not sent unless required.
 8. Authors should correct their galley proofs very carefully and preferably twice. An additional correction by a colleague always proves to be useful. Particular attention should be paid to chemical formulas, mathematical equations, symbols, medical nomenclature etc. Any system of correction marks can be used in a clear manner, preferably with a red pen. Additions or clarifications are allowed provided that they improve the presentation but do not bring new results (no fee).
 9. Articles submitted to AR may be rejected without review if:
 - they do not fall within the journal's policy.
 - they do not follow the instructions to authors.
 - language is unclear.
 - results are not sufficient to support a final conclusion.
 - results are not objectively based on valid experiments.
 - they repeat results already published by the same or other authors before the submission to AR.
 - plagiarism is detected by plagiarism screening services.(Rejection rate (2015): 64%).
 10. Authors who wish to prepare a review should contact the Managing Editor of the journal in order to get confirmation of interest in the particular topic of the review. The expression of interest by the Managing Editor does not necessarily imply acceptance of the review by the journal.
 11. Authors may inquire information about the status of their manuscript(s) by calling the Editorial Office at +30-22950-53389, Monday to Friday 9.00-16.00 (Athens time), or by sending an e-mail to journals@iiar-anticancer.org
 12. Authors who wish to edit a special issue on a particular topic should contact the Managing Editor.
 13. Authors, Editors and Publishers of books are welcome to submit their books for immediate review in AR. There is no fee for this service.
- (This text is a combination of advice and suggestions contributed by Editors, Authors, Readers and the Managing Editor of AR).

Copyright© 2016 - International Institute of Anticancer Research (J.G. Delinasios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.